Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 14/20 | 0.41 |
| ▸ | CTSL | P07711 | 13/20 | 0.41 |
| ▸ | CTSK | P43235 | 10/20 | 0.41 |
| ▸ | METAP2 | P50579 | 3/20 | 0.40 |
| ▸ | METAP1 | P53582 | 3/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | MC3R | P41968 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4796963 | 0.88 | CTSS (0.40) | CTSSCTSLCTSKMETAP2METAP1 | |
| SCHEMBL4796447 | 0.88 | KMT2A (0.43) | CTSSCTSLCTSKMETAP2METAP1 | |
| SCHEMBL4797750 | 0.84 | CTSS (0.45) | CTSSCTSLCTSKMETAP2METAP1 | |
| SCHEMBL4798054 | 0.83 | CTSS (0.51) | CTSSCTSLCTSKMETAP2METAP1 | |
| SCHEMBL4800287 | 0.82 | CTSL (0.44) | CTSSCTSLCTSKMETAP2METAP1 | |
| SCHEMBL4796328 | 0.81 | CTSL (0.40) | CTSSCTSLCTSKMETAP2METAP1 | |
| SCHEMBL4798327 | 0.81 | METAP2 (0.42) | CTSSCTSLCTSKMETAP2METAP1 | |
| SCHEMBL4799148 | 0.81 | CTSS (0.44) | CTSSCTSLCTSKMETAP2METAP1 | |
| SCHEMBL4801319 | 0.79 | EPHX2 (0.49) | CTSSCTSLCTSKMETAP2METAP1 | |
| SCHEMBL4797862 | 0.79 | CTSS (0.48) | CTSSCTSLCTSKMETAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | claimed |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | disclosed |
| US-7384970-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-06-10 | — | — | US | disclosed |
| US-20040248887-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248887-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSL 11/4885CTSK 9/4885 |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSL 11/4885CTSK 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.